Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion description "[We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion evidence source_evidence_literature NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion SIO_000772 21942328 NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion wasDerivedFrom befree-2016 NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_assertion wasGeneratedBy ECO_0000203 NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.
- befree-2016 importedOn "2016-02-19" NP925923.RAo4UXE55mJiT78aKlsxzUN1mazeng9HwJoLHR5KBjaTE130_provenance.